Perspective
Volume 14:02, 2023

Journal of AIDS & Clinical Research

ISSN: 2155-6113 Open Access

Patterns in the Pervasiveness of Hepatitis B Infection, Hepatitis C Infection and HIV Diseases in Iranian Patients with Genetic Draining Problems

Hertis Areen*

Department of Neurology, Huntington Center North Rhine-Westphalia, Ruhr-University, Bochum, Germany

Introduction

Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are major public health concerns worldwide, causing significant morbidity and mortality. This article provides a comprehensive review of HBV and HCV, including their epidemiology, modes of transmission, clinical manifestations, diagnostic approaches, treatment options, and prevention strategies. Understanding the similarities and differences between these two viruses is crucial for effective management, prevention, and control efforts. Hepatitis B virus and hepatitis C virus are two distinct blood borne pathogens that primarily affect the liver. Chronic infections with HBV and HCV can lead to progressive liver disease, including cirrhosis, liver failure, and hepatocellular carcinoma. This review aims to provide a comprehensive understanding of the epidemiology, clinical aspects, diagnosis, treatment, and prevention strategies related to HBV and HCV infections. HBV and HCV infections are major global health burdens, with varying prevalence across different regions. HBV is more prevalent in areas such as sub-Saharan Africa and East Asia, while HCV is more common in certain regions of Europe, North Africa, and parts of Asia. High-risk populations for HBV and HCV transmission include injection drug users, individuals with multiple sexual partners, healthcare workers, and infants born to infected mothers [1,2].

Description

HBV and HCV can be transmitted through similar routes, including perinatal transmission, unprotected sexual intercourse, injection drug use, and occupational exposure to infected blood. However, HBV is more contagious and can also spread through close personal contact, sharing of contaminated items, and vertical transmission from mother to child during childbirth [3]. Both HBV and HCV infections can present as acute or chronic hepatitis, although the majority of cases progress to chronicity in HCV infection compared to HBV. Acute hepatitis may be asymptomatic or manifest as flu-like symptoms, while chronic infections can lead to long-term liver damage. The clinical spectrum ranges from mild chronic hepatitis to cirrhosis and hepatocellular carcinoma. Accurate diagnosis of HBV and HCV infections is essential for appropriate management and treatment [4]. Serological tests detect specific antibodies and viral antigens, while molecular assays detect viral genetic material. These tests help differentiate between acute and chronic infections, assess viral load, and determine the need for treatment. Additionally, liver function tests, imaging studies, and liver biopsy may be employed to evaluate liver damage [5,6].

***Address for Correspondence:** Hertis Areen, Department of Neurology, Huntington Center North Rhine-Westphalia, Ruhr-University, Bochum, Germany, E-mail: hertisa@gmail.com*

Received: 03 April, 2023, Manuscript No. jar-23-101550; **Editor Assigned:** 05 April, 2023, PreQC No. P-101550; **Reviewed:** 17 April, 2023, QC No. Q-101550; **Revised:** 22 April, 2023, Manuscript No. R-101550; **Published:** 29 April, 2023, DOI: 10.37421/2155-6113.2023.14.938

Conclusion

Hepatitis B virus and hepatitis C virus infections pose substantial challenges to global public health. Understanding the epidemiology, modes of transmission, clinical manifestations, diagnosis, treatment, and prevention strategies for HBV and HCV is crucial for effective disease management. By implementing comprehensive prevention measures, expanding access to diagnostics and treatment, and investing in research and innovation, we can make significant strides in reducing the burden of HBV and HCV infections and improving the liver health of populations worldwide. Despite significant progress in prevention and treatment, challenges remain in combating HBV and HCV infections. These include limited access to diagnostics and treatment in resource-limited settings, the high cost of medications, and the existence of undiagnosed cases. Ongoing research and efforts are focused on developing more effective vaccines, exploring new therapeutic targets, and improving access to affordable diagnostics and treatment options.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Rezvan, H., H. Abolghassemi and S. Amini Kafiabad. "Transfusion-transmitted infections among multitransfused patients in Iran: a review." *Transfus Med* 17 (2007): 425-433.
2. Samimi-Rad, Katayoun, Ramin Rahimnia, Mahdi Sadeghi and Seyed Amir Malekpour, et al. "Epidemic history of hepatitis C virus among patients with inherited bleeding disorders in Iran." *Plos one* 11 (2016): 0162492.
3. Smith, Bryce D., Rebecca L. Morgan, Geoff A. Beckett and Yngve Falck-Ytter, et al. "Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention." *Ann Intern Med* 157 (2012): 817-822.
4. Pierce, Glenn F., Megan Adediran, Saliou Diop and Amy L. Dunn, et al. "Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years." *Lancet Haematol* 9 (2022): 689-697.
5. Soucie, J. Michael, Lisa C. Richardson, Bruce Lee Evatt and Jeanne V. Linden, et al. "Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males." *Transfusion* 41 (2001): 338-343.
6. Abolghasemi, H., M. Maghsudlu, S. Amini Kafi-Abad and A. Cheraghali. "Introduction to Iranian blood transfusion organization and blood safety in Iran." *Iran J Public Health* 38 (2009): 82-87.

How to cite this article: Areen, Hertis. "Patterns in the Pervasiveness of Hepatitis B Infection, Hepatitis C Infection and HIV Diseases in Iranian Patients with Genetic Draining Problems." *J AIDS Clin Res* 14 (2023): 938.